vs
ASTEC INDUSTRIES INC（ASTE）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
ASTEC INDUSTRIES INCの直近四半期売上が大きい（$400.6M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.4倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 3.0%、差は13.5%）。ASTEC INDUSTRIES INCの前年同期比売上増加率が高い（11.6% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $7.4M）。過去8四半期でASTEC INDUSTRIES INCの売上複合成長率が高い（13.8% vs 1.2%）
ASTECは香港に本社を置く国際的な電子企業で、主に電源装置と電力変換ハードウェアを製造しています。コンピュータシステム用電源の世界的な主要サプライヤーの一つで、一時期は世界最大の電源メーカーでした。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ASTE vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $400.6M | $283.4M |
| 純利益 | $12.0M | $46.7M |
| 粗利率 | 27.3% | 55.5% |
| 営業利益率 | 5.7% | 29.1% |
| 純利益率 | 3.0% | 16.5% |
| 売上前年比 | 11.6% | -2.4% |
| 純利益前年比 | -43.1% | -23.5% |
| EPS（希薄化後） | $0.52 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $400.6M | $283.4M | ||
| Q3 25 | $350.1M | $274.1M | ||
| Q2 25 | $330.3M | $249.5M | ||
| Q1 25 | $329.4M | $296.5M | ||
| Q4 24 | $359.0M | $290.3M | ||
| Q3 24 | $291.4M | $283.8M | ||
| Q2 24 | $345.5M | $267.1M | ||
| Q1 24 | $309.2M | $277.0M |
| Q4 25 | $12.0M | $46.7M | ||
| Q3 25 | $-4.2M | $42.2M | ||
| Q2 25 | $16.7M | $47.5M | ||
| Q1 25 | $14.3M | $50.1M | ||
| Q4 24 | $21.1M | $61.0M | ||
| Q3 24 | $-6.2M | $54.4M | ||
| Q2 24 | $-14.0M | $49.1M | ||
| Q1 24 | $3.4M | $49.5M |
| Q4 25 | 27.3% | 55.5% | ||
| Q3 25 | 24.1% | 55.3% | ||
| Q2 25 | 26.7% | 56.2% | ||
| Q1 25 | 28.1% | 57.3% | ||
| Q4 24 | 28.7% | 55.5% | ||
| Q3 24 | 22.9% | 55.5% | ||
| Q2 24 | 23.5% | 54.7% | ||
| Q1 24 | 24.9% | 54.8% |
| Q4 25 | 5.7% | 29.1% | ||
| Q3 25 | 0.3% | 29.1% | ||
| Q2 25 | 6.5% | 28.8% | ||
| Q1 25 | 6.2% | 29.8% | ||
| Q4 24 | 9.7% | 31.7% | ||
| Q3 24 | -2.5% | 29.7% | ||
| Q2 24 | -3.1% | 27.0% | ||
| Q1 24 | 2.0% | 29.7% |
| Q4 25 | 3.0% | 16.5% | ||
| Q3 25 | -1.2% | 15.4% | ||
| Q2 25 | 5.1% | 19.0% | ||
| Q1 25 | 4.3% | 16.9% | ||
| Q4 24 | 5.9% | 21.0% | ||
| Q3 24 | -2.1% | 19.2% | ||
| Q2 24 | -4.1% | 18.4% | ||
| Q1 24 | 1.1% | 17.9% |
| Q4 25 | $0.52 | $0.97 | ||
| Q3 25 | $-0.18 | $0.86 | ||
| Q2 25 | $0.72 | $0.95 | ||
| Q1 25 | $0.62 | $1.00 | ||
| Q4 24 | $0.92 | $1.22 | ||
| Q3 24 | $-0.27 | $1.09 | ||
| Q2 24 | $-0.61 | $0.98 | ||
| Q1 24 | $0.15 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.1M | $62.4M |
| 総負債低いほど良い | — | $1.0B |
| 株主資本純資産 | $681.7M | $1.8B |
| 総資産 | $1.4B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $74.1M | $62.4M | ||
| Q3 25 | $71.8M | $119.1M | ||
| Q2 25 | $91.6M | $139.5M | ||
| Q1 25 | $95.4M | $97.9M | ||
| Q4 24 | $93.8M | $50.9M | ||
| Q3 24 | $58.9M | $51.5M | ||
| Q2 24 | $68.4M | $34.3M | ||
| Q1 24 | $63.8M | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $681.7M | $1.8B | ||
| Q3 25 | $668.9M | $1.8B | ||
| Q2 25 | $674.9M | $1.9B | ||
| Q1 25 | $653.2M | $1.8B | ||
| Q4 24 | $637.8M | $1.8B | ||
| Q3 24 | $631.4M | $1.7B | ||
| Q2 24 | $633.3M | $1.7B | ||
| Q1 24 | $650.3M | $1.7B |
| Q4 25 | $1.4B | $3.5B | ||
| Q3 25 | $1.3B | $3.4B | ||
| Q2 25 | $1.1B | $3.4B | ||
| Q1 25 | $1.1B | $3.4B | ||
| Q4 24 | $1.0B | $3.3B | ||
| Q3 24 | $1.1B | $3.3B | ||
| Q2 24 | $1.1B | $3.3B | ||
| Q1 24 | $1.1B | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $36.1M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $7.4M | $75.3M |
| FCFマージンFCF / 売上 | 1.8% | 26.6% |
| 設備投資強度設備投資 / 売上 | 7.2% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 3.01× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $20.7M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $36.1M | $78.3M | ||
| Q3 25 | $-8.1M | $57.5M | ||
| Q2 25 | $12.9M | $79.0M | ||
| Q1 25 | $20.5M | $61.8M | ||
| Q4 24 | $36.6M | $65.1M | ||
| Q3 24 | $22.5M | $69.8M | ||
| Q2 24 | $10.9M | $54.8M | ||
| Q1 24 | $-47.0M | $66.9M |
| Q4 25 | $7.4M | $75.3M | ||
| Q3 25 | $-12.3M | $55.4M | ||
| Q2 25 | $9.0M | $78.2M | ||
| Q1 25 | $16.6M | $58.4M | ||
| Q4 24 | $32.1M | $63.5M | ||
| Q3 24 | $19.9M | $67.8M | ||
| Q2 24 | $3.3M | $53.6M | ||
| Q1 24 | $-52.8M | $63.8M |
| Q4 25 | 1.8% | 26.6% | ||
| Q3 25 | -3.5% | 20.2% | ||
| Q2 25 | 2.7% | 31.3% | ||
| Q1 25 | 5.0% | 19.7% | ||
| Q4 24 | 8.9% | 21.9% | ||
| Q3 24 | 6.8% | 23.9% | ||
| Q2 24 | 1.0% | 20.1% | ||
| Q1 24 | -17.1% | 23.0% |
| Q4 25 | 7.2% | 1.1% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 1.2% | 0.3% | ||
| Q1 25 | 1.2% | 1.2% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 0.9% | 0.7% | ||
| Q2 24 | 2.2% | 0.4% | ||
| Q1 24 | 1.9% | 1.1% |
| Q4 25 | 3.01× | 1.68× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | 0.77× | 1.66× | ||
| Q1 25 | 1.43× | 1.23× | ||
| Q4 24 | 1.73× | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | -13.82× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ASTE
| Infrastructure Group | $208.7M | 52% |
| Material Solutions | $105.3M | 26% |
| Parts And Component Sales | $58.3M | 15% |
| Other | $15.3M | 4% |
| Service And Equipment Installation Revenue | $6.9M | 2% |
| Cargo And Freight | $6.1M | 2% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
